Does Fosamax Cause Osteonecrosis of the Jaw?

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

Legacy of General Health Information

The legacy of general health and science information dissemination has long served as a foundational resource for public understanding of medical conditions and treatments. This heritage, rooted in community health centers and broad educational outreach, provides a baseline for individuals to engage with complex health topics. Within this context, discussions of medication side effects and patient safety are standard, yet they often remain at a general level, addressing population-wide risks without delving into specific exposure scenarios. Transitioning from this broad foundation, a more focused inquiry emerges when considering the occupational and environmental dimensions of pharmaceutical exposure.

Bridging to Targeted Exposure Concerns

The pivot from general health information to a targeted concern involves recognizing that certain patient populations may face heightened risks due to prolonged or high-dose exposure to specific medications. This shift in perspective moves the discussion from a universal health education framework to a more nuanced examination of how individual exposure histories, particularly in clinical or manufacturing settings, can influence adverse outcomes. The bridge concept thus reframes the legacy of general health awareness into a specific lens on exposure risk, setting the stage for a detailed exploration of causation without yet invoking mechanistic claims or external evidence.

Clinical Evidence and Pharmacological Mechanisms

Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The question of whether Fosamax causes ONJ requires careful examination of clinical evidence, pharmacological mechanisms, and risk factors. Clinical evidence from FDA-approved labeling indicates that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The labeling explicitly states that ONJ is generally associated with invasive dental procedures such as tooth extraction, dental implants, or boney surgery, as well as local infection, and that known risk factors include diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Mechanistic pathways linking Fosamax to ONJ are supported by multiscale characterization of jawbone, which provides comprehensive information to help understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This suggests that the unique biology of the jawbone may make it particularly susceptible to the effects of bisphosphonates, which suppress bone turnover by inhibiting osteoclast activity. Over time, this suppression can impair the jawbone's ability to remodel and heal after minor trauma, such as tooth extraction, leading to necrotic bone exposure.

Adequacy of Warnings and Causation Considerations

Regarding the adequacy of warnings, the FDA-approved labeling for Fosamax includes a dedicated section on ONJ under 'Warnings and Precautions' (Section 5.4), which describes the condition, associated risk factors, and the potential for increased risk with longer exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The labeling also notes that in placebo-controlled clinical studies of Fosamax, the percentages of patients with symptoms such as jaw pain were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This indicates that while ONJ is a recognized adverse event, its incidence in clinical trials was not significantly elevated compared to placebo, suggesting that the condition is rare and often associated with additional risk factors. For affected patients, causation considerations involve evaluating the timeline between exposure and documented harm. The labeling reports that the time to onset of symptoms varied from one day to several months after starting the drug, and that most patients had relief of symptoms after stopping (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). A subset of patients experienced recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This pattern supports a causal relationship in some individuals, particularly those with additional risk factors such as dental procedures or cancer therapy. However, the labeling also emphasizes that ONJ can occur spontaneously, meaning it is not exclusively caused by bisphosphonates. In summary, the evidence indicates that Fosamax is associated with an increased risk of ONJ, particularly in patients with known risk factors and longer duration of use. The FDA-approved labeling provides adequate warnings about this risk, including recommendations for dental evaluation and consideration of drug discontinuation before invasive dental procedures. For patients who develop ONJ, the timeline of symptom onset after starting Fosamax and resolution after discontinuation supports a causal link in some cases, though the condition is multifactorial. Clinicians should weigh the benefits of Fosamax for fracture prevention against the rare but serious risk of ONJ, especially in patients with additional risk factors.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and how is it used?

What is osteonecrosis of the jaw (ONJ)?

Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).